A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862 · MAHOGANY Phase 3Active, not recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 799 (actual)
- Start date
- 10 Mar 2022
- Primary completion
- Jul 2028 (estimated)
- Study completion
- 1 Jun 2030
- Last update posted
- 15 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 4
Interventions
- Zanubrutinib Drug
- Rituximab Drug
- Lenalidomide Drug
- Obinutuzumab Drug
Conditions and primary outcome
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
Primary outcome
Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC) (Approximately 78 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05100862.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05100862 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.